Published in Pediatr Nephrol on April 23, 2010
C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol (1999) 7.15
C-reactive protein and the risk of developing hypertension. JAMA (2003) 5.75
Hyperuricemia induces endothelial dysfunction. Kidney Int (2005) 5.36
Atherosclerosis is an inflammatory disease. Am Heart J (1999) 5.12
Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol (2005) 3.73
Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension (2004) 3.51
Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis (1996) 3.41
Obesity hypertension in children: a problem of epidemic proportions. Hypertension (2002) 3.30
Oscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: a multicenter trial including 1141 subjects. J Pediatr (1997) 3.29
Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens (2002) 3.21
Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension (2001) 3.04
Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension (2004) 2.46
Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J (1998) 1.97
Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem (1991) 1.95
Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension (2000) 1.87
Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens (2001) 1.75
Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens (1994) 1.66
Nontraditional cardiovascular risk factors in pediatric metabolic syndrome. J Pediatr (2006) 1.65
Uric acid, evolution and primitive cultures. Semin Nephrol (2005) 1.49
Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int (2004) 1.42
Mean platelet volume measurement, EDTA or citrate? Hematology (2006) 1.38
Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy. N Engl J Med (1984) 1.34
Thrombopoietin and mean platelet volume in coronary artery disease. Clin Cardiol (2001) 1.31
Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens (2008) 1.31
Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol (2004) 1.27
High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens (2003) 1.27
Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum (2006) 1.27
Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res (2006) 1.24
Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. Hypertens Res (2008) 1.05
Mechanisms of vascular damage in gout and oxalosis: crystal induced, granulocyte mediated, endothelial injury. Thromb Haemost (1983) 1.02
The mean platelet volume in patients with essential and white coat hypertension. Platelets (2005) 1.01
Platelet activation and inflammatory response in patients with non-dipper hypertension. Atherosclerosis (2009) 0.98
Megakaryocytes and platelets in vascular disease. Baillieres Clin Haematol (1997) 0.97
Elevated blood pressure, race/ethnicity, and C-reactive protein levels in children and adolescents. Pediatrics (2008) 0.96
Decreased nitric oxide levels and increased calcium content in platelets of hypertensive patients. Am J Hypertens (2001) 0.94
High-sensitivity C-reactive protein is a good marker of cardiovascular risk in obese children and adolescents. Eur J Endocrinol (2008) 0.94
Relation of C-reactive protein and tumor necrosis factor-alpha to ambulatory blood pressure variability in healthy adults. Am J Cardiol (2006) 0.93
The role of uric acid in pediatric hypertension. J Ren Nutr (2007) 0.89
The fructose nation. J Am Soc Nephrol (2007) 0.88
Serum uric acid and ambulatory blood pressure in children with primary hypertension. Pediatr Res (2008) 0.88
Lifestyle modification decreases the mean platelet volume in prehypertensive patients. Platelets (2009) 0.88
Cytoplasmic free [Ca2+] is increased in the platelets of spontaneously hypertensive rats and essential hypertensive patients. Clin Sci (Lond) (1985) 0.87
Role of C-reactive protein in cardiovascular disease. Ann Pharmacother (2004) 0.87
Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy. Mol Med (2000) 0.86
[Parameters of uric acid metabolism in healthy children and in patients with arterial hypertension]. Pediatriia (1990) 0.85
Are C-reactive protein and homocysteine cardiovascular risk factors in obese children and adolescents? Pediatr Int (2008) 0.84
Thrombocytopenia and macrothrombocytosis in gestational hypertension. Br J Obstet Gynaecol (1981) 0.82
Evidence of platelet activation in hypertension. J Hum Hypertens (1997) 0.80
Increased platelet volume--sign of impaired thrombopoiesis in diabetes mellitus. Klin Wochenschr (1989) 0.80
Oxidative stress and cardiovascular disease. Can J Cardiol (1997) 0.80
Study of platelet adhesion in patients with uncomplicated hypertension. J Hypertens (1996) 0.79
[Body mass index in the school age children and youth from the city of Lodz]. Pol Merkur Lekarski (2007) 0.79
Prothrombotic megakaryocyte and platelet changes in hypertension are reversed following treatment: a pilot study. Platelets (2001) 0.78
Markers of systemic inflammation in children with hyperuricemia. Acta Paediatr (2012) 1.48
Assessment of lithogenic risk in children based on a morning spot urine sample. J Urol (2010) 1.45
KIM-1 and NGAL: new markers of obstructive nephropathy. Pediatr Nephrol (2011) 1.23
Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity? Pediatr Nephrol (2010) 1.11
A new approach to the diagnosis of children's urolithiasis based on the Bonn Risk Index. Pediatr Nephrol (2008) 0.92
Hypertension in dialysed children: the prevalence and therapeutic approach in Poland--a nationwide survey. Nephrol Dial Transplant (2005) 0.91
MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. Pediatr Nephrol (2006) 0.90
Normative data on the Bonn Risk Index for calcium oxalate crystallization in healthy children. Pediatr Nephrol (2007) 0.89
Effect of cyclosporin A on proteinuria in the course of glomerulopathy associated with WT1 mutations. Eur J Pediatr (2010) 0.86
Response to prednisone in relation to NR3C1 intron B polymorphisms in childhood nephrotic syndrome. Pediatr Nephrol (2008) 0.81
Urinary monocyte chemoattractant protein-1 excretion in children with glomerular proteinuria. Scand J Urol Nephrol (2010) 0.81
Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children. Pediatr Nephrol (2010) 0.81
Evaluation of bladder instability in children with recurrent urinary tract infections. Med Sci Monit (2002) 0.81
Assessment of serum cystatin C in children with congenital solitary kidney. Pediatr Nephrol (2006) 0.81
A potential pathogenic role of oxalate in autism. Eur J Paediatr Neurol (2011) 0.80
Expression of glucocorticoid receptors in mononuclear cells in nephrotic syndrome. Pediatr Nephrol (2003) 0.80
Expression of P-glycoprotein in lymphocytes from children with nephrotic syndrome, depending on their steroid response. Pediatr Nephrol (2006) 0.79
Functional bladder capacity and urine osmolality in children with primary monosymptomatic nocturnal enuresis. Scand J Urol Nephrol (2005) 0.79
Glucocorticoid receptor and vascular endothelial growth factor in nephrotic syndrome. Acta Paediatr (2006) 0.78
A need to establish normative data for plasma oxalates. Am J Kidney Dis (2008) 0.78
Reference values of plasma oxalate in children and adolescents. Pediatr Nephrol (2008) 0.78
Is plasma symmetric dimethylarginine a suitable marker of renal function in children and adolescents? Scand J Urol Nephrol (2011) 0.78
[Serum and urinary homocysteine in children with steroid-dependent nephrotic syndrome]. Pol Merkur Lekarski (2011) 0.77
[WT1 mutation as a cause of progressive nephropathy in Frasier syndrome--case report]. Pol Merkur Lekarski (2009) 0.77
[Chronic peritoneal dialysis in infants--preliminary results of the multicenter survey]. Przegl Lek (2006) 0.76
Urinary transforming growth factor beta1 in children and adolescents with congenital solitary kidney. Pediatr Nephrol (2008) 0.76
Laminin and transforming growth factor beta-1 in children with vesicoureteric reflux. Pediatr Nephrol (2008) 0.76
Is symmetric dimethylarginine a sensitive biomarker of subclinical kidney injury in children born with low birth weight? Biomarkers (2014) 0.76
Serum and urine leptin concentration in children with nephrotic syndrome. Pediatr Nephrol (2005) 0.75
High-sensitivity C-reactive protein (hs-CRP) level in children with nephrotic syndrome. Pediatr Nephrol (2006) 0.75
Expression of glucocorticoid receptors in nephrotic children depending on total prednisone dose. J Pediatr Endocrinol Metab (2005) 0.75
Urinary MMP-9/NGAL ratio as a potential marker of FSGS in nephrotic children. Dis Markers (2013) 0.75
Asymmetric and symmetric dimethylarginine in adolescents with hyperuricemia. Dis Markers (2013) 0.75
The effects of breastfeeding on serum asymmetric dimethylarginine levels and body composition in children. Breastfeed Med (2014) 0.75
[Evaluation of inflammatory and renal injury markers in youngest children with pyelonephritis]. Pol Merkur Lekarski (2008) 0.75
IgA nephropathy in a girl with psoriasis and seronegative arthritis. Pediatr Dermatol (2008) 0.75
[The role of early-life metabolic programming in the pathogenesis of lifestyle diseases]. Dev Period Med (2015) 0.75
[Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in the urine of children with pyelonephritis]. Pol Merkur Lekarski (2009) 0.75
[Urinary laminin and fibronectin level in children with nephritic syndrome]. Pol Merkur Lekarski (2009) 0.75
[Analysis of vesicoureteral reflux (VUR) course in children]. Pol Merkur Lekarski (2008) 0.75
[The concentration of plasma anion oxalate in children treatment antibiotics beta lactame]. Pol Merkur Lekarski (2006) 0.75
Vascular endothelial growth factor in children with nephrotic syndrome treated with cyclosporine A. Acta Paediatr (2006) 0.75
Spontaneous urinary calcium oxalate crystallization in hypercalciuric children. Pediatr Nephrol (2009) 0.75
[Assessment of transforming growth factor-beta1 in serum of children with idiopathic nephrotic syndrome depending on the way of treatment]. Pol Merkur Lekarski (2003) 0.75
[Role of matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP) in nephrology]. Przegl Lek (2009) 0.75
Expression of multidrug resistance P-glycoprotein on lymphocytes from nephrotic children treated with cyclosporine A and ACE-inhibitor. Eur J Pediatr (2006) 0.75
[Reference values of 24-hour ambulatory blood pressure in healthy children by height]. Pol Merkur Lekarski (2004) 0.75
[The evaluation of urinary tract dysfunction in children with monosymptomatic primary nocturnal enuresis]. Pol Merkur Lekarski (2008) 0.75
Increased circulating inflammatory markers may indicate that formula-fed children are at risk of atherosclerosis. Acta Paediatr (2014) 0.75
[The effect of cyclosporine A in steroid-dependent nephrotic syndrome in children]. Pol Merkur Lekarski (2005) 0.75
[Assessment of 24-hour blood pressure function of the single kidney in children with renal agenesis]. Pol Merkur Lekarski (2005) 0.75
[Serum and urinary concentration of selected metalloproteinases and their tissue inhibitors in children with vesicoureteral reflux]. Pol Merkur Lekarski (2010) 0.75
[Urinary TGF-beta1 excretion in children with renal cysts]. Przegl Lek (2006) 0.75
Serum and urine fibronectin levels in children with vesicoureteral reflux. Pediatr Nephrol (2007) 0.75